HUE053247T2 - Mieloszuppresszió kezelése - Google Patents
Mieloszuppresszió kezeléseInfo
- Publication number
- HUE053247T2 HUE053247T2 HUE13787651A HUE13787651A HUE053247T2 HU E053247 T2 HUE053247 T2 HU E053247T2 HU E13787651 A HUE13787651 A HU E13787651A HU E13787651 A HUE13787651 A HU E13787651A HU E053247 T2 HUE053247 T2 HU E053247T2
- Authority
- HU
- Hungary
- Prior art keywords
- myelosuppression
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644623P | 2012-05-09 | 2012-05-09 | |
US201261644556P | 2012-05-09 | 2012-05-09 | |
US201261648043P | 2012-05-16 | 2012-05-16 | |
US201261653362P | 2012-05-30 | 2012-05-30 | |
US201261664611P | 2012-06-26 | 2012-06-26 | |
US201261668709P | 2012-07-06 | 2012-07-06 | |
US201261678053P | 2012-07-31 | 2012-07-31 | |
US201261702207P | 2012-09-17 | 2012-09-17 | |
US201261724836P | 2012-11-09 | 2012-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE053247T2 true HUE053247T2 (hu) | 2021-06-28 |
Family
ID=49549076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13787651A HUE053247T2 (hu) | 2012-05-09 | 2013-03-13 | Mieloszuppresszió kezelése |
Country Status (21)
Country | Link |
---|---|
US (6) | US9271999B2 (hu) |
EP (2) | EP3785720A1 (hu) |
JP (3) | JP6177885B2 (hu) |
KR (2) | KR102452803B1 (hu) |
CN (3) | CN104411316B (hu) |
AU (1) | AU2013260101B2 (hu) |
BR (1) | BR112014028094B1 (hu) |
CA (2) | CA2872855C (hu) |
CL (2) | CL2014003017A1 (hu) |
DK (1) | DK2846809T3 (hu) |
EA (1) | EA029382B1 (hu) |
ES (1) | ES2848050T3 (hu) |
HK (1) | HK1207574A1 (hu) |
HU (1) | HUE053247T2 (hu) |
IL (1) | IL235593B (hu) |
LT (1) | LT2846809T (hu) |
MX (2) | MX370567B (hu) |
PL (1) | PL2846809T3 (hu) |
PT (1) | PT2846809T (hu) |
SG (3) | SG10201603059YA (hu) |
WO (1) | WO2013169355A1 (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201603059YA (en) | 2012-05-09 | 2016-05-30 | Cantex Pharmaceuticals Inc | Treatment Of Myelosuppression |
SG11201603081WA (en) * | 2013-10-22 | 2016-05-30 | Cantex Pharmaceuticals Inc | Methods of treating and preventing radiation damage |
WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
WO2016133910A1 (en) * | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
KR20180027563A (ko) | 2015-07-13 | 2018-03-14 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린 조성물 |
US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
SG11201810872UA (en) | 2016-06-06 | 2019-01-30 | Beyondspring Pharmaceuticals Inc | Composition and method for reducing neutropenia |
EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
JP2020514412A (ja) | 2017-02-01 | 2020-05-21 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | 好中球減少症の低減方法 |
CN107569486A (zh) * | 2017-08-23 | 2018-01-12 | 北京京佑奇康生物科技有限公司 | 孟鲁司特钠治疗血小板减少症的新用途 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019147615A1 (en) * | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
MX2021008928A (es) * | 2019-01-25 | 2021-11-04 | Janssen Pharmaceutica Nv | Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química. |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
WO2021041532A1 (en) * | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
MX2022005812A (es) * | 2019-11-13 | 2022-08-16 | Taiho Pharmaceutical Co Ltd | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
WO2021207697A1 (en) | 2020-04-10 | 2021-10-14 | Cantex Pharmaceuticals, Inc. | Treatment of acute lung injury |
KR20230058289A (ko) | 2021-10-21 | 2023-05-03 | 숙명여자대학교산학협력단 | 혈액암 치료를 위한 글리세오플빈 병용요법 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
FR2553287B1 (fr) | 1983-10-18 | 1986-09-12 | Choay Sa | Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire |
DE3422518A1 (de) | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen |
FR2584606A1 (fr) | 1985-07-12 | 1987-01-16 | Dropic | Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif |
US5380716A (en) | 1988-12-15 | 1995-01-10 | Glycomed, Inc. | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
IT1234826B (it) | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
WO1991015216A1 (en) | 1990-04-05 | 1991-10-17 | Kennedy Thomas P | Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases |
US5250519A (en) | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
IT1254216B (it) | 1992-02-25 | 1995-09-14 | Opocrin Spa | Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
WO1993019734A1 (en) | 1992-04-02 | 1993-10-14 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
US5306724A (en) | 1992-08-17 | 1994-04-26 | Clintec Nutrition Company | Method for preventing and treating atherosclerosis |
GB2270841A (en) | 1992-09-09 | 1994-03-30 | Merck & Co Inc | Compositions for Treating vascular restenosis |
US5696100A (en) | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
US5296471A (en) | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
AU6246394A (en) | 1993-02-22 | 1994-09-14 | Cavalier Pharmaceuticals, Inc. | Use of heparin to inhibit interleukin-8 |
SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
US5840707A (en) | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
AU2435795A (en) | 1994-05-06 | 1995-11-29 | Glycomed Incorporated | O-desulfated heparin derivatives, methods of making and uses thereof |
US5804560A (en) | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
ATE280496T1 (de) | 1996-07-29 | 2004-11-15 | Paringenix Inc | Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin |
US6154502A (en) | 1996-08-22 | 2000-11-28 | Intel Corporation | Signal constellation slicer |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
NZ337364A (en) | 1997-02-15 | 2001-06-29 | Millennium Pharm Inc | Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB |
WO1998053852A1 (en) | 1997-05-30 | 1998-12-03 | Arch Development Corporation | P-selectin translocation to vascular epithelial lumen by ionizing radiation |
US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
CA2351067A1 (en) | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Method of treating heparin-induced thrombocytopenia |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
US6514502B1 (en) | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
EP1223948A2 (en) | 1999-09-13 | 2002-07-24 | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center | Method of inhibiting nf-kappa-b with heparin, for treating cardiovascular diseases and inflammations |
US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
US20050026811A1 (en) | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
EA007322B1 (ru) * | 2001-04-18 | 2006-08-25 | Прометик Байосайенсиз, Инк. | Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов |
WO2003088980A1 (en) | 2002-04-18 | 2003-10-30 | Embury Stephen H | Method and composition for preventing pain in sickle cell patients |
AU2003251829B2 (en) | 2002-07-09 | 2009-12-10 | Radical Therapeutix | Method to inhibit ischemia and reperfusion injury |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US20080207895A1 (en) | 2002-11-27 | 2008-08-28 | Rosenberg Robert D | Methods for synthesizing polysaccharides |
US20040180812A1 (en) | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
US7538096B2 (en) | 2004-03-16 | 2009-05-26 | The General Hospital Corporation | Treatment and prevention of abnormal cellular proliferation |
EP2407169A1 (en) * | 2004-04-22 | 2012-01-18 | Celator Pharmaceuticals, Inc. | Combination formulations of anthracycline agents and cytidine analogs |
US20050261241A1 (en) | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
US7468358B2 (en) | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
JP2006076968A (ja) | 2004-09-10 | 2006-03-23 | Seikagaku Kogyo Co Ltd | 生理活性分子含有架橋ヘパリンゲル組成物 |
ZA200801696B (en) | 2005-07-22 | 2009-08-26 | Univ California | Heparin compositions and selection inhibition |
WO2007019554A2 (en) | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
JP5156382B2 (ja) | 2005-09-30 | 2013-03-06 | タカラバイオ株式会社 | T細胞集団の製造方法 |
BRPI0619999A2 (pt) | 2005-12-16 | 2011-10-25 | Dnp Canada Inc | derivados de quitina para hiperlipidemia |
WO2007115372A1 (en) | 2006-04-10 | 2007-10-18 | Monash University | A method of modulating beta-amyloid peptide production |
RU2468820C2 (ru) | 2006-07-26 | 2012-12-10 | Интрексон Корпорейшн | Способы и композиции для лечения заболевания |
CA2663521A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
CA2678587A1 (en) | 2007-02-28 | 2008-09-04 | Paringenix, Inc. | O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease |
JP5579057B2 (ja) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス, エルエルシー | 再発性癌の処置のための方法および組成物 |
EP2170354A1 (en) | 2007-07-23 | 2010-04-07 | University of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
US20090238852A1 (en) | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
EP2281008B1 (en) | 2008-04-04 | 2017-01-04 | University of Utah Research Foundation | Alkylated and sulfated hyaluronan compounds, methods for their preparation and use thereof |
US8476249B2 (en) * | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
WO2011038901A1 (en) | 2009-09-29 | 2011-04-07 | Activaero Gmbh | Improved method for treatment of patients with cystic fibrosis |
AU2011226755A1 (en) | 2010-03-12 | 2012-10-04 | The Australian National University | Heparan sulfate replacement therapy |
JP5829672B2 (ja) | 2010-03-24 | 2015-12-09 | レ ラボラトワール セルヴィエ | 結腸直腸及び胃腸癌の予防 |
EP2588119A4 (en) | 2010-06-28 | 2014-01-08 | Stemtech Internat Inc | METHOD AND COMPOSITIONS FOR IMPROVING STRAIN CELL MOBILIZATION |
EP2670396A1 (en) * | 2011-01-31 | 2013-12-11 | Celgene Corporation | Pharmaceutical compositions of cytidine analogs and methods of use thereof |
US20120196828A1 (en) | 2011-02-01 | 2012-08-02 | Paringenix, Inc. | Sensitization of cancer cells to treatment |
WO2013016181A1 (en) | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
CA2872104A1 (en) | 2012-05-01 | 2013-11-07 | Duke University | Compositions and methods for heparan sulfate as a biomarker for transplant rejection |
SG10201603059YA (en) | 2012-05-09 | 2016-05-30 | Cantex Pharmaceuticals Inc | Treatment Of Myelosuppression |
CA2908227A1 (en) | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
SG11201603081WA (en) | 2013-10-22 | 2016-05-30 | Cantex Pharmaceuticals Inc | Methods of treating and preventing radiation damage |
WO2015061604A1 (en) | 2013-10-24 | 2015-04-30 | Thomas Kennedy | Treating bacterial infections of the lung |
WO2015142924A1 (en) | 2014-03-17 | 2015-09-24 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
US20160243168A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Adoptive cell transfer methods |
WO2016133910A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
US20170106011A1 (en) | 2015-10-20 | 2017-04-20 | Cantex Pharmaceuticals, Inc. | Methods of treating traumatic brain injury and sequelae |
WO2017123549A1 (en) | 2016-01-11 | 2017-07-20 | Cantex Pharmaceuticals, Inc. | Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids |
-
2013
- 2013-03-13 SG SG10201603059YA patent/SG10201603059YA/en unknown
- 2013-03-13 ES ES13787651T patent/ES2848050T3/es active Active
- 2013-03-13 CA CA2872855A patent/CA2872855C/en active Active
- 2013-03-13 EP EP20189050.6A patent/EP3785720A1/en not_active Withdrawn
- 2013-03-13 SG SG10201914117QA patent/SG10201914117QA/en unknown
- 2013-03-13 EP EP13787651.2A patent/EP2846809B1/en active Active
- 2013-03-13 DK DK13787651.2T patent/DK2846809T3/da active
- 2013-03-13 CN CN201380036055.1A patent/CN104411316B/zh not_active Expired - Fee Related
- 2013-03-13 PL PL13787651T patent/PL2846809T3/pl unknown
- 2013-03-13 BR BR112014028094-0A patent/BR112014028094B1/pt not_active IP Right Cessation
- 2013-03-13 HU HUE13787651A patent/HUE053247T2/hu unknown
- 2013-03-13 LT LTEP13787651.2T patent/LT2846809T/lt unknown
- 2013-03-13 WO PCT/US2013/031053 patent/WO2013169355A1/en active Application Filing
- 2013-03-13 KR KR1020207028539A patent/KR102452803B1/ko active IP Right Grant
- 2013-03-13 SG SG11201407340YA patent/SG11201407340YA/en unknown
- 2013-03-13 MX MX2014013633A patent/MX370567B/es active IP Right Grant
- 2013-03-13 US US13/801,990 patent/US9271999B2/en not_active Expired - Fee Related
- 2013-03-13 CA CA3122808A patent/CA3122808A1/en not_active Abandoned
- 2013-03-13 CN CN201810295102.9A patent/CN108498532B/zh not_active Expired - Fee Related
- 2013-03-13 JP JP2015511452A patent/JP6177885B2/ja not_active Expired - Fee Related
- 2013-03-13 PT PT137876512T patent/PT2846809T/pt unknown
- 2013-03-13 AU AU2013260101A patent/AU2013260101B2/en not_active Ceased
- 2013-03-13 CN CN202110756600.0A patent/CN113521093A/zh active Pending
- 2013-03-13 KR KR1020147034512A patent/KR102165348B1/ko active IP Right Grant
- 2013-03-13 EA EA201492052A patent/EA029382B1/ru not_active IP Right Cessation
- 2013-08-09 US US13/963,526 patent/US8734804B2/en active Active
-
2014
- 2014-11-07 MX MX2019009437A patent/MX2019009437A/es unknown
- 2014-11-07 CL CL2014003017A patent/CL2014003017A1/es unknown
- 2014-11-09 IL IL235593A patent/IL235593B/en active IP Right Grant
-
2015
- 2015-08-25 HK HK15108246.8A patent/HK1207574A1/xx unknown
-
2016
- 2016-01-20 US US15/001,773 patent/US20160213706A1/en not_active Abandoned
-
2017
- 2017-03-21 JP JP2017054390A patent/JP6448694B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-16 US US15/923,470 patent/US20180296590A1/en not_active Abandoned
- 2018-10-01 JP JP2018186702A patent/JP6726252B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-15 US US16/541,660 patent/US11229664B2/en active Active
-
2021
- 2021-01-04 CL CL2021000008A patent/CL2021000008A1/es unknown
- 2021-12-14 US US17/550,942 patent/US20220354882A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207574A1 (en) | Treatment of myelosuppression | |
EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
HK1205759A1 (en) | Treatment of biomass | |
GB201506561D0 (en) | Treatment of amblyopia | |
HK1214128A1 (zh) | 癌症的治療 | |
HK1211213A1 (en) | Treatment of diseases involving mucin | |
HK1202053A1 (en) | Treatment of liver conditions | |
GB201217892D0 (en) | Treatment of cancer | |
HK1204956A1 (en) | Treatment of cancer | |
GB201309274D0 (en) | Treatment Of Fuel | |
ZA201501038B (en) | Treatment of wax | |
GB201207907D0 (en) | Treatment of depression | |
GB201217890D0 (en) | Treatment of cancer | |
GB201221118D0 (en) | Methods of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment | |
GB201206326D0 (en) | Methods of treatment | |
GB201206325D0 (en) | Methods of treatment | |
GB201206330D0 (en) | Methods of treatment | |
GB201206324D0 (en) | Methods of treatment | |
IL233740A0 (en) | Treatment of liver diseases | |
GB201221032D0 (en) | Method of treatment | |
GB201219092D0 (en) | Treatment of cardiovascular disease | |
GB201207894D0 (en) | Method of treatment | |
GB201211135D0 (en) | Treatment |